期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

奈必洛尔在慢性心力衰竭治疗中的研究进展

Review of Nebivolol in Patient with Chronic Heart Failure
下载PDF
导出
摘要 奈必洛尔是第三代β受体阻滞剂,具有很高的β1/β2选择性。奈必洛尔不仅通过抑制交感神经系统,改善心力衰竭症状及预后,还可刺激一氧化氮生成,产生血管扩张作用,是迄今为止唯一被临床试验证实对老年心力衰竭患者(无论其射血分数如何)有效的β受体阻滞剂。未来的研究需要进一步明确其在不同类型心力衰竭患者中的地位。 Nebivolol is a third-generation β-blocker with high β1/β2 selectivity.Nebivolol not only inhibits the sympathetic nervous system,improves heart failure prognosis,but also has vasodilating properties through the stimulation of the production of nitric oxide.Nebivolol is the only β-blocker shown to be effective in elderly heart failure patients,regardless of their left ventricular ejection fraction.Future studies will be needed to further clarify nebivolol＇s role in the treatment of patients with heart failure.
作者 谢琳刚 廖忠友
机构地区 成都军区峨眉疗养院疗养二科
出处 《心血管病学进展》 CAS 2011年第3期374-377,共4页 Advances in Cardiovascular Diseases
关键词 慢性心力衰竭 奈必洛尔 一氧化氮 交感神经系统 Β受体阻滞剂 chronic heart failure nebivolol nitric oxide sympathetic nervous system β-blocker
分类号 R541.6 [医药卫生—心血管疾病]
  • 相关文献

参考文献36

  • 1Lloyd-Jones D, Adams R, Camethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [ J ]. Circulation, 2009,119 ( 5 ) : e21- e181.
  • 2Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers [ J ]. Eur Heart J, 2004,25 ( 15 ) : 1341- 1362.
  • 3Veverka A, Salinas JL. Nebivolol in the treatment of chronic heart failure[ J]. Vasc Health Risk Manag, 2007,3 ( 5 ) :647 -654.
  • 4Brixius K, Bundkirchen A, Bolck B, et al. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium[J]. Br J Pharmacol, 2001,133(8) :1330-1338.
  • 5Rozec B, Erfanian M, Laurent K, et at. Nebivolol, a vasodilating selective beta ( 1 ) -blocker, is a beta( 3 ) -adrenoceptor agonist in the nonfailing transplanted human heart[J]. J Am Coil Cardiol, 2009,53(17) :1532-1538.
  • 6Sule SS, Frishman W. Nebivolol: new therapy update[ J]. Cardiol Rev, 2006, 14(5) :259-264.
  • 7Cheng JW. Nebivolol : a third-generation beta-blocker for hypertension [ J ]. Clin Ther, 2009,31(3) :447462.
  • 8Grassi G, Trevano FQ, Facchini A, et al. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized muhicentre trial[ J ]. Blood Press Suppl, 2003,2:35- 40.
  • 9Celik T, Iyisoy A, Kursaklioglu H, et al. Comparative effects of nebivolot and metoprolol on oxidative stress, insulin resistance, plasma adiponeetin and soluble P-setectin levels in hypertensive patients[J]. Hypertension, 2006,24(3) : 591-596.
  • 10Triposkiadis F, Karayannis G, Giamouzis G, et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications [J]. J Am Coll Cardiol, 2009,54(19) :1747-1762.
心血管病学进展
2011年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部